Dr. Dahiya is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Education & Training
UMass Chan - BaystateFellowship, Hematology and Medical Oncology, 2013 - 2016- UMass Chan - BaystateResidency, Internal Medicine, 2010 - 2012
Western Reserve Health Education/NEOMEDInternship, Internal Medicine, 2009 - 2010
Maulana Azad Medical CollegeClass of 2008
Certifications & Licensure
CA State Medical License 2016 - 2025
MD State Medical License 2017 - 2022
MA State Medical License 2014 - 2018
OH State Medical License 2009 - 2014
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.Courtney J Smith, Anmol Goyal, Brian R Smith, Dasom Lee, Alexandria Jensen
Ejhaem. 2025-04-01 - Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refract...Loretta J Nastoupil, Ashley Bonner, Pearl Wang, Lamees Almuallem, Jigar Desai
Experimental Hematology & Oncology. 2025-03-05 - Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.Laura Samples, Hossein Sadrzadeh, Matthew J Frigault, Caron A Jacobson, Mehdi Hamadani
Blood. 2025-02-12
Abstracts/Posters
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T ConsortiumSaurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...Saurabh Dahiya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical TrialsClinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
CAR-T Warning for Secondary Malignancies: Warranted or Not?January 5th, 2025- COVID-19 Prevention Must Extend Beyond Vaccines for Patients Receiving Cell TherapiesApril 19th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
